Dorsey & Whitney Trust CO LLC Makes New $236,000 Investment in Organon & Co. (NYSE:OGN)

Dorsey & Whitney Trust CO LLC bought a new position in shares of Organon & Co. (NYSE:OGN) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 15,796 shares of the company’s stock, valued at approximately $236,000.

Other large investors have also recently added to or reduced their stakes in the company. Barclays PLC increased its holdings in Organon & Co. by 238.0% during the 3rd quarter. Barclays PLC now owns 119,483 shares of the company’s stock worth $2,285,000 after purchasing an additional 84,136 shares in the last quarter. Weiss Asset Management LP bought a new position in Organon & Co. during the 3rd quarter worth about $32,966,000. Cerity Partners LLC increased its holdings in Organon & Co. by 94.0% during the 3rd quarter. Cerity Partners LLC now owns 667,340 shares of the company’s stock worth $12,766,000 after purchasing an additional 323,308 shares in the last quarter. Foundry Partners LLC bought a new position in Organon & Co. during the 3rd quarter worth about $7,642,000. Finally, Robeco Institutional Asset Management B.V. bought a new position in Organon & Co. during the 4th quarter worth about $2,263,000. Institutional investors own 77.43% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Morgan Stanley reduced their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Friday, February 14th. Barclays reduced their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Finally, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Organon & Co. presently has an average rating of “Hold” and a consensus target price of $20.80.

Organon & Co. Trading Down 0.3 %

Shares of NYSE:OGN opened at $15.69 on Wednesday. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10. The company has a market capitalization of $4.05 billion, a P/E ratio of 4.71, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. The company has a 50-day simple moving average of $15.46 and a 200 day simple moving average of $16.80. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Sell-side analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Investors of record on Monday, February 24th will be paid a $0.28 dividend. The ex-dividend date of this dividend is Monday, February 24th. This represents a $1.12 annualized dividend and a yield of 7.14%. Organon & Co.’s dividend payout ratio (DPR) is currently 33.63%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.